Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03605953 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT03605953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03605953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Central Hospital, Nancy, France
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2018
Completion date
April 1, 2021
Enrollment
134 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell (hsc) transplantation